Demographics | Within 3 months(1st group) | 3–6 months(2nd group) | 6–9 months(3rd group) | 9–12 months(4th group) | 12–24 months(5th group) | 24–60 months(6th group) | >60 months(7th group) |
---|---|---|---|---|---|---|---|
Sex | |||||||
Male eyes | 12 | 13 | 22 | 33 | 42 | 42 | 34 |
Female eyes | 0 | 0 | 5 | 0 | 7 | 4 | 7 |
Age, years | 19.42±6.57 | 17.77±4.07 | 15.00±4.73 | 18.61±5.79 | 17.67±4.41 | 20.24±5.26 | 25.20±8.34 |
Disease duration, months | 1.75±0.97 | 4.31±0.48 | 7.70±1.14 | 11.00±0.87 | 18.51±4.08 | 39.11±8.74 | 118.76±67.20 |
BCVA (LogMAR) | 1.65±0.44 | 1.58±0.44 | 1.71±0.37 | 1.79±0.42 | 1.64±0.51 | 1.75±0.39 | 1.49±0.36 |
BCVA, best-corrected visual acuity; LogMAR, logarithm of the minimum angle of resolution; 1st group, disease duration ≤3 months; 2nd group, disease duration 3–6 months; 3rd group, disease duration 6–9 months; 4th group, disease duration 9–12 months; 5th group, disease duration 12–24 months; 6th group, disease duration 24–60 months; 7th group, disease duration >60 months.